U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
NEW YORK, May 12, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) securities between February 29, 2016 and May 4, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
